[Clinical Presentation of Tuberculosis in Routine Practice]

Overview

Journal Z Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2012 Jul 21

PMID 22815006

Citations 1

Authors

R Dinser

M Frerix

U Muller-Ladner

Affiliations

Soon will be listed here.

Abstract

Since the beginning of the biologics era tuberculosis is known to be a potential life-threatening complication during treatment of patients with rheumatic diseases. National and international societies have developed recommendations for tuberculosis screening and treatment of patients at risk for development of tuberculosis. Owing to the relative rareness of overt tuberculosis in patients with rheumatic diseases, the experience of individual rheumatologists with this complication is limited. Therefore, we have analyzed the tuberculosis cases from 2006-2011 in our rheumatology referral center (treating more than 1,500 inpatient and 8,000 outpatient cases every year) to obtain a real-life picture more than 10 years after initiation of the first application of biologics outside of controlled clinical trials. We identified 4 cases that illustrate the difficulties of diagnosis and treatment.

Citing Articles

[Inflammatory rheumatic diseases in migrants].

Kotter I, Krusche M Inn Med (Heidelb). 2023; 64(5):426-434.

PMID: 37099225 DOI: 10.1007/s00108-023-01514-0.

References

Sellam J, Hamdi H, Roy C, Baron G, Lemann M, Puechal X . Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis. 2007; 66(12):1610-5. PMC: 2095326. DOI: 10.1136/ard.2007.069799. View

. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982; 60(4):555-64. PMC: 2536088. View

Diel R, Hauer B, Loddenkemper R, Manger B, Kruger K . [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases]. Z Rheumatol. 2009; 68(5):411-6. DOI: 10.1007/s00393-009-0475-x. View

Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J . Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis. 2009; 69(1):181-5. DOI: 10.1136/ard.2008.101857. View

Iguchi T, Yokoyama K, Mitsuishi M, Chen C, Ikeda Y, Okamoto S . [Pulmonary tuberculosis and adenovirus-hemorrhagic cystitis after autologous peripheral blood stem cell transplantation for follicular lymphoma]. Rinsho Ketsueki. 2006; 46(9):1049-54. View

Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis A . Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol. 2008; 35(7):1271-6. View

Ewer K, Millington K, Deeks J, Alvarez L, Bryant G, Lalvani A . Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2006; 174(7):831-9. DOI: 10.1164/rccm.200511-1783OC. View

Solovic I, Sester M, Gomez-Reino J, Rieder H, Ehlers S, Milburn H . The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010; 36(5):1185-206. DOI: 10.1183/09031936.00028510. View

Merlo A, Saverino D, Tenca C, Grossi C, Bruno S, Ciccone E . CD85/LIR-1/ILT2 and CD152 (cytotoxic T lymphocyte antigen 4) inhibitory molecules down-regulate the cytolytic activity of human CD4+ T-cell clones specific for Mycobacterium tuberculosis. Infect Immun. 2001; 69(10):6022-9. PMC: 98730. DOI: 10.1128/IAI.69.10.6022-6029.2001. View

10.

Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M . Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009; 60(7):1884-94. PMC: 2921546. DOI: 10.1002/art.24632. View

11.

Gomez-Reino J, Carmona L, Descalzo M . Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007; 57(5):756-61. DOI: 10.1002/art.22768. View

12.

Malaviya A, Kapoor S, Garg S, Rawat R, Shankar S, Nagpal S . Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report. J Rheumatol. 2009; 36(7):1414-20. DOI: 10.3899/jrheum.081042. View

13.

Rybar I, Rozborilova E, Zanova E, Micekova D, Solovic I, Rovensky J . The effectiveness for prevention of tuberculosis in patients with inflammatory rheumatic diseases treated with TNF inhibitors. Bratisl Lek Listy. 2008; 109(4):164-7. View

14.

Mariette X, Baron G, Tubach F, Liote F, Combe B, Miceli-Richard C . Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis. 2012; 71(11):1783-90. DOI: 10.1136/annrheumdis-2011-200408. View

15.

Carmona L, Gomez-Reino J, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Martin Mola E . Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005; 52(6):1766-72. DOI: 10.1002/art.21043. View

16.

Samandari T, Agizew T, Nyirenda S, Tedla Z, Sibanda T, Shang N . 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011; 377(9777):1588-98. DOI: 10.1016/S0140-6736(11)60204-3. View

17.

Dixon W, Hyrich K, Watson K, Lunt M, Galloway J, Ustianowski A . Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2009; 69(3):522-8. PMC: 2927681. DOI: 10.1136/ard.2009.118935. View

18.

Murakami S, Takeno M, Kirino Y, Kobayashi M, Watanabe R, Kudo M . Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis. Tuberculosis (Edinb). 2009; 89(2):136-41. DOI: 10.1016/j.tube.2008.12.004. View

19.

Mack U, Migliori G, Sester M, Rieder H, Ehlers S, Goletti D . LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009; 33(5):956-73. DOI: 10.1183/09031936.00120908. View

20.

Denis B, Lefort A, Flipo R, Tubach F, Lemann M, Ravaud P . Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect. 2007; 14(2):183-6. DOI: 10.1111/j.1469-0691.2007.01891.x. View